Kaken Pharmaceutical said on December 26 that it is out-licensing its STAT6 program, including the preclinical oral agent KP-723 for Type 2 inflammatory diseases, to Johnson & Johnson in a deal worth up to nearly US$1.25 billion. The company also…
To read the full story
Related Article
- Kaken Set to Take Stab at US Market with Vascular Malformation Drug
February 20, 2025
BUSINESS
- Japan Clears Fujirebio’s Blood-Based Aβ42 Test for Alzheimer’s
November 19, 2026
- Sobi Japan to Take Over Orfadin from Astellas in December
November 19, 2026
- Shionogi Closes US$2 Billion IntraBio Buyout, Gains Rare Disease Drug
November 19, 2026
- AbbVie Japan Launches Skyrizi 55 mg for Pediatric Psoriasis
November 19, 2026
- Japan Drug Makers’ H1 Sales Surge 14.7% as Weak Yen Fuels Growth
November 18, 2026
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…





